Comprehensive assessment of 5 interleukin inhibitors for the treatment of psoriasis: scientific guidance based on drug selection recommendations for Chinese medical institutions
Until the guideline recommendations, the National Essential Drug List, clinical studies, and many other dimensions of this assessment are updated, ixekizumab, secukinumab, and ustekinumab, which have the top 3 scores, can be used as a priority recommendation for Chinese medical institutions to select interleukin inhibitors and optimise the use of the drug catalog based on the scoring results of this assessment.
Authors
- Sha Lai
- Zhi-Kun Qiu (ORCID: https://orcid.org/0000-0003-3463-8750)
- J Zhang (ORCID: https://orcid.org/0009-0004-9261-0718)
- Wen-Wei Li
Institutions
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Publication Details
- Journal
- Journal of Pharmaceutical Policy and Practice
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1080/20523211.2025.2567960
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00